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Abstract 
Background: Most patients with multiple myeloma (MM) will relapse after an initial response and eventually suc-
cumb to their disease. This is due to the persistence of chemotherapy-resistant tumor cells in the patients’ bone mar-
row (BM) and immunotherapeutic approaches could contribute to eradicating these remaining cells. We evaluated 
SLLP1 as a potential immunotherapeutic target for MM.
Methods: We determined SLLP1 expression in myeloma cell lines and 394 BM samples from myeloma patients 
(n = 177) and BM samples from healthy donors (n = 11). 896 blood samples and 64 BM samples from myeloma 
patients (n = 263) and blood from healthy donors (n = 112) were analyzed for anti-SLLP1 antibodies. Seropositive 
patients were evaluated regarding SLLP1-specific T cells.
Results: Most cell lines showed SLLP1 RNA and protein expression while it was absent from normal BM. Of 177 
patients 41% evidenced SLLP1 expression at least once during the course of their disease and 44% of newly 
diagnosed patients were SLLP1-positive. Expression of SLLP1 was associated with adverse cytogenetics and with 
negative prognostic factors including the patient’s age, number of BM-infiltrating plasma cells, serum albumin, β2-
microglobulin, creatinine, and hemoglobin. Among patients treated with allogeneic stem cell transplantation those 
with SLLP1 expression showed a trend towards a reduced overall survival. Spontaneous anti-SLLP humoral immunity 
was detectable in 9.5% of patients but none of the seropositive patients evidenced SLLP1-specific T cells. However, 
antigen-specific T cells could readily be induced in vitro after stimulation with SLLP1.
Conclusions: SLLP1 represents a promising target for the immunotherapy of MM, in particular for the adoptive trans-
fer of T cell receptor-transduced T cells.
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Background
Multiple myeloma (MM) is an incurable plasma cell 
(PC) malignancy, which develops in the bone mar-
row (BM) and eventually causes renal insufficiency, 
immunosuppression with repeated infections, anemia, 
and bone lesions with hypercalcemia. There have been 
significant therapeutic advances over the past decade and 
the median survival of myeloma patients has increased 
to approximately 6 years [1]. However, most patients will 
still eventually suffer a fatal relapse after an initially effec-
tive therapy. This is due to the persistence of chemother-
apy-resistant myeloma-propagating cells [2–4] in the BM 
even after destruction of the bulk of tumor cells by con-
ventional therapies [5–8] and, accordingly, the disease 
will become more and more refractory to chemotherapy 
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after each additional line of treatment. We, therefore, 
believe that MM needs to be attacked from different bio-
logical angles by a variety of modalities, including immu-
notherapeutic approaches, to destroy the tumor bulk as 
well as myeloma-propagating residual disease and even-
tually achieve cures.
One prerequisite for the development of effective can-
cer immunotherapies is the identification of appropriate 
target antigens. Cancer-testis antigens (CTA) are a fam-
ily of proteins which show an expression restricted to 
different malignancies and normal germ-line tissues and 
are capable of eliciting spontaneous cellular and humoral 
immune responses against a variety of tumors [9]. Anti-
gen SLLP1, which is encoded by gene SPACA3, was 
first described as a unique, non-bacteriolytic lysozyme-
like protein expressed in the acrosome of human sperm 
[10]. Later, SLLP1 was found to be a member of the CTA 
family of antigens and a preliminary study detected its 
expression in different hematologic malignancies [11]. 
However, so far no broad analysis has been performed 
regarding SLLP1 expression in MM, its expression has 
never been correlated with clinicopathological charac-
teristics of the patients, and its ability to evoke specific 
humoral and T cell responses has not been explored.
Methods
Cell lines
Human myeloma cell lines AMO-1, MOLP-8, RPMI-
8226, KMS-12-BM, EJM, IM-9, U-266, OPM-2, and LP-1, 
chronic myeloid leukemia cell line K562, and human 
embryonic kidney cell line 293 were newly obtained from 
the German Collection of Microorganisms and Cell Cul-
tures (DSMZ, Braunschweig, Germany). Two additional 
human myeloma cell lines, Brown and SK-007, were pro-
vided by the New York branch of the Ludwig Institute for 
Cancer Research (LICR). Upon arrival in our laboratory, 
the authenticity of the cell lines was verified using cytol-
ogy and flow cytometry. All cell lines were maintained 
in RPMI 1640 medium (Invitrogen, Carlsbad, CA, USA) 
with penicillin–streptomycin (Invitrogen) and 10% fetal 
calf serum (Lonza, Basel, Switzerland).
Patients and healthy donors
For SLLP1 expression analyses we consecutively col-
lected 394 bone marrow samples from a total of 177 
myeloma patients. In addition, BM samples of 11 dif-
ferent healthy donors, who provided BM for allogeneic 
stem cell transplantation, were obtained. For the analyses 
of antibody responses a total of 896 blood samples and 
64 BM samples were obtained from a different cohort of 
263 myeloma patients, and 112 blood samples were col-
lected from healthy blood donors. BM and blood samples 
from patients were obtained during routine diagnostic 
procedures. Healthy subjects and patients, who were 
admitted for treatment at the University Medical Center 
Hamburg-Eppendorf, gave written informed consent in 
accordance with the revised version of the Declaration 
of Helsinki. The study protocol had been approved by the 
local ethics committee (decision number OB-038/06). 
For the preparation of plasma samples, whole BM or 
peripheral blood was centrifuged at 680g and the super-
natants were frozen at −80°C. Mononuclear cells were 
isolated from blood and BM samples by density gradient 
centrifugation.
Reverse transcription‑polymerase chain reaction (RT‑PCR)
Total RNA was extracted from BM mononuclear cells 
(BMMC) and myeloma cell lines using the RNeasy Mini 
kit (Qiagen, Hilden, Germany) and reverse transcribed 
to complementary DNA (cDNA) applying avian myelo-
blastosis virus (AMV) reverse transcriptase (Promega, 
Madison, WI, USA). RNA derived from human testis was 
obtained from Applied Biosystems (Carlsbad, CA, USA). 
Primers for qualitative PCR amplification of SLLP1 
cDNA (Forward: 5′-AAGCTCTACGGTCGTTGTGAA 
CTG-3′; Reverse: 5′-CTAGAAGTCACAGCCATCCAC 
CCA-3′) and the cDNA for the housekeeping gene glyc-
eraldehyde-3-phosphate dehydrogenase (GAPDH; For-
ward: 5′-TGATGACATCAAGAAGGTGG-3′; Reverse: 
5′-TTTCTTACTCCTTGGAGGCC-3′) were obtained 
from MWG Biotech (Ebersberg, Germany). Conven-
tional PCR was performed as previously described [12]. 
All RT–PCR experiments were performed at least twice. 
To assess primer specificity, PCR products were analyzed 
repeatedly by DNA sequence analysis.
Western blot analysis
Whole cell protein extracts were prepared in RIPA 
buffer containing a cocktail of protease inhibitors 
(Sigma, Steinheim, Germany). Testis lysate used as 
a positive control was obtained from Abnova (Tai-
pei, Taiwan). 293 cells were transfected with an SLLP1 
expression plasmid (Origene, Rockville, MD) using 
Lipofectamine 2000 (Lifetechnologies) and harvested 
after 3 days. Protein concentrations were determined by 
BCA assay (Thermo Scientific) and immunoblot analy-
sis was performed as previously described [13] apply-
ing 80  µg of protein per lane. The primary antibodies 
were a rabbit polyclonal antibody against human SLLP1 
(Sigma) used at a dilution of 1:1,000 and a mouse anti-
human monoclonal antibody against β-actin (ACTB; 
Cell Signaling Technology, Danvers, MA) used at a 
dilution of 1:3,000. Secondary antibodies were an HRP-
labeled anti-rabbit monoclonal antibody (R&D Systems, 
Minneapolis, MN, USA) used at a dilution of 1:2,000 or 
an HRP-labeled anti-mouse monoclonal antibody (R&D 
Page 3 of 12Yousef et al. J Transl Med  (2015) 13:197 
Systems, Minneapolis, MN, USA) used at a dilution of 
1:3,000, respectively. Specific antibody binding was vis-
ualized by chemiluminescence (PerkinElmer, Waltham, 
MA, USA).
Flow cytometry
For the analysis of cytoplasmic SLLP1 protein expression, 
myeloma cell lines were fixed using FACS Lysing Solu-
tion, followed by permeabilization with Permeabilizing 
Solution (both from BD Biosciences). Cells were stained 
with a rabbit polyclonal antibody against human SLLP1 
(Sigma) or an appropriate isotype control antibody fol-
lowed by incubation with a secondary FITC-conjugated 
goat anti-rabbit IgG antibody from Jackson ImmunoRe-
search (Suffolk, UK). Samples were analyzed using a 
FACSCalibur cytometer (BD Biosciences, Franklin Lakes, 
NJ, USA) and FlowJo software (Tree Star, Ashland, OR, 
USA).
Enzyme‑linked immunosorbent assay (ELISA)
A set of 20-mer SLLP1 peptides (n  =  21) overlapping 
by 10 amino acids and spanning the complete protein 
sequence was obtained from Peptides&Elephants (Pots-
dam, Germany). Recombinant influenza nucleoprotein 
(NP) expressed in E. coli was purchased from Imgenex 
(San Diego, CA, USA), tetanus toxoid (TT) was provided 
by Chiron Behring (Marburg, Germany), and recombi-
nant SSX-2 protein was provided by the LICR. 96-well-
plates were coated over night at 4°C with recombinant 
protein or peptides diluted in PBS at a final concentration 
of 1 μg/ml. Plates were blocked with PBS containing 3% 
milk powder for 2 h at room temperature (RT). Sera were 
added to the plates and incubated for 2 h at RT. A sec-
ondary AP-conjugated anti-human-IgG antibody (South-
ern Biotech, Birmingham, AL, USA) was applied for 1 h 
at RT. Detection reagent para-nitrophenyl phosphate 
(PNPP; Southern Biotech) was added to the plates for 
30 min and specific absorption was measured at 405 nm 
using a Sunrise™ ELISA reader (Tecan, Crailsheim, 
Germany).
Generation of peptide‑loaded dendritic cells
For the generation of dendritic cells (DC) monocytes 
were obtained through plastic adherence. Briefly, PBMCs 
were seeded into 75  cm2 flasks for 2  h. Non-adherent 
cells were removed by extensive washing. The remain-
ing monocytes were incubated in DC medium CellGro 
(CellGenix, Freiburg, Germany) for 5  days in the pres-
ence of 200  IU/ml interleukin (IL)-4 (R&D Systems) 
and 100  IU/ml granulocyte macrophage colony-stim-
ulating factor (GM-CSF; R&D Systems) to induce an 
immature DC phenotype. Restimulation with cytokines 
was performed on days 2 and 5. At day 6 a pool of 
peptides containing overlapping 20-mer SLLP1 pep-
tides (Peptides&Elephants) at a concentration of 20 µM, 
respectively, was added to the culture. After 2 h a matu-
ration cocktail was added containing tumor necrosis fac-
tor (TNF)-α (5 ng/ml), IL-1β (5 ng/ml), IL-6 (150 ng/ml; 
all R&D Systems), and prostaglandin (PGE)2 (1  µg/ml; 
Sigma). The maturation status of the DCs was assessed 
the next day by flow cytometry using anti-HLA DR, 
CD80, CD86, CD83, and CD14 monoclonal antibod-
ies (BioLegend, San Diego, CA, USA). Peptide-loaded, 
mature DCs were either used directly or cryopreserved 
for later use.
Induction of SLLP1‑specific T cells
The monocyte-depleted PBMC fraction was seeded 
at ratio of 1:10 with autologous peptide-loaded DCs 
in 96-well plates in RPMI (5% human serum, 1% pen/
strep) in the presence of IL-2 (Roche Diagnostics, Rot-
kreuz, Switzerland) and IL-7 (R&D Systems) at 10  ng/
ml. Restimulation with cytokines and DCs was carried 
out weekly at ratios of 1:20 to 1:40. Specificity assess-
ment was performed after 2–3 rounds of restimulation 
by interferon (IFN)-γ enzyme-linked immunosorb-
ent spot (ELISPOT) assay as previously described [14]. 
Briefly, 2.5 × 104 T cells were cocultured with 5 × 104 
autologous PHA blasts serving as T-APC [15] in the 
presence or absence of SLLP1 peptides overnight in 
anti-IFN-γ-coated (Mabtech, Stockholm, Sweden) 
nitrocellulose plates (Millipore, Bedford, MA, USA). 
Following development, spots were counted using an 
AID EliSpot reader and EliSpot software version 3.2.3 
(Autoimmun Diagnostika, Strassberg, Germany). For 
enrichment and single cell isolation of SLLP1-spe-
cific T cells up to 1 ×  106 T cells were incubated with 
CFSE-labeled T-APC at a ratio of 1:1 in the presence or 
absence of cognate SLLP1 peptide in X-Vivo15 medium 
(Bio Whittaker, Verviers, Belgium). IFN-γ-positive T 
cells were FACS-sorted using the IFN-γ Secretion Assay 
(Miltenyi Biotech, Bergisch Gladbach, Germany) as 
described previously [16]. Clonality was determined by 
flow cytometry by the use of a set of 24 different TCR v 
beta antibodies (IO Test; Beckman Coulter). The TCR 
chain composition was assessed by PCR using a primer 
set against TRBV chains and TRAV chains as previously 
described [17, 18].
Statistical analysis
Correlations between clinicopathological parameters 
and CT antigen expression were assessed using Pearson’s 
Chi-square test. Log-Rank test and Cox-regression analy-
sis were performed for evaluation of survival and relapse 
in MM patients. Results were considered significant if 
p < 0.05.
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Results
SLLP1 is expressed in myeloma cells but is absent 
from healthy bone marrow
In a first step, we analyzed SLLP1 RNA expression in dif-
ferent myeloma cell lines using qualitative RT-PCR. We 
found the majority (8/11) of cell lines tested to evidence 
SLLP1 expression (Figure 1a). As expected for a cancer-
testis antigen, SLLP1 RNA was also present in normal 
testis tissue but, importantly, it was absent from the 
whole BM of 11 healthy donors analyzed (Figure 1a) thus 
indicating a tumor-restricted expression of SLLP1. Next, 
we confirmed SLLP1 protein expression in myeloma 
cell lines, testis lysate, and 293 cells transfected with an 
SLLP1 expression plasmid using western blot analyses 
(Figure 1b). The observed band at 15 kDa corresponds to 
the calculated and previously described molecular weight 
of cleaved SLLP1 [11]. Applying flow cytometry for the 
analysis of SLLP1 on a single-cell level we did not detect 
convincing expression of SLLP1 on the surface of any of 
our myeloma cell lines (data not shown). However, we 
observed strong SLLP1 protein expression in the cyto-
plasm of all lines that had also evidenced presence of the 
CTA as indicated by western blot (Figure 1c).
SLLP1 expression in myeloma patients and its relation 
to clinicopathological characteristics and prognosis
Analyzing the clinicopathological characteristics of all 
177 patients (Table 1), we found the typical patient to be 
male with a median age of 54 years (range 28–83 years). 
Importantly, there were no significant differences with 
regard to age and sex between the SLLP1-positive and 
the SLLP-negative subgroups of patients. Most patients 
were diagnosed at later stages of the disease and the 
most common idiotype was IgG kappa. While 52 (29%) 
of the patients were included immediately after initial 
diagnosis, most patients had already received therapy 
before this study was initiated. Out of all 177 patients 
approximately 41% showed expression of SLLP1 RNA in 
their BM at least once throughout the whole course of 
their disease (Table 1). Looking at only newly diagnosed 
patients we found about 44% to be SLLP1-positive (data 
not shown). The only clinicopathological parameter cor-
relating with the expression of SLLP1 were cytogenet-
ics with 9 out of 11 patients with a t(4;14) translocation 
being SLLP1-positive (Table  1). This finding also held 
true when we focused on the untreated patients with 
all 6 patients evidencing a t(4;14) being SLLP1-positive 
(p < 0.004).
From our MM patients we were able to collect a 
total of 394 BM samples with a median number of two 
(range 1–9) samples per patient over a median period of 
3.8  months (range 0–53  months). Of all these samples 
about one quarter evidenced expression of SLLP1 RNA 
(Table 2). Correlating the expression data with the clini-
cal data of the patients at the time the BM sample was 
collected, we found SLLP1 expression to be associated 
with a number of negative prognostic factors includ-
ing the patient’s age, the number of BM-infiltrating 
plasma cells, as well as serum levels of albumin, β2-
microglobulin, hemoglobin, and creatinine. Importantly, 
we also observed a strong correlation with the treat-
ment status of the patient with untreated patients most 
frequently showing SLLP1 expression in their BM and 
patients who had undergone alloSCT evidencing the low-
est positivity rates (Table 2).
Patients who had received alloSCT also seemed to rep-
resent a unique subgroup when it came to the relation 
between SLLP1 expression in the BM and the patients’ 
prognosis. We did not observe an effect of BM-standing 
SLLP1 expression on the clinical outcome of all 177 mye-
loma patients included or of the 52 newly diagnosed and 
untreated patients (data not shown). However, we found 
that among patients treated with alloSCT those who had 
evidenced SLLP1 expression in their BM at least at one 
time point after transplant showed a progression-free 
survival (Figure  2a), which was not significantly shorter 
(p = 0.21), and a trend (p = 0.07) towards a shorter over-
all survival (Figure 2b) compared to patients who always 
remained SLLP1-negative.
Myeloma patients develop spontaneous antibody 
responses against SLLP1
We next asked the question whether SLLP1 would 
be capable of evoking spontaneous humoral immune 
responses in patients with MM. Using two pools of over-
lapping SLLP1 peptides in an ELISA assay we analyzed a 
total of 896 peripheral blood and 64 BM plasma samples 
from 263 myeloma patients. We found SLLP1-specific 
IgG antibodies in a total of 44 (4.9%) serum samples. 22 
(2.5%) samples were positive for peptide pool SLLP1–1, 
15 (1.7%) for peptide pool SLLP1–2, and 7 (0.8%) sera 
evidenced antibodies against both peptide pools (Fig-
ure 3a). We also found anti-SLLP1 antibody responses in 
1 (1.6%) and 3 (4.7%) of BM-derived sera from 64 mye-
loma patients for peptide pools SLLP1–1 and SLLP1–2, 
respectively (Figure  3a). Overall, out of all patients, 25 
(9.5%) evidenced anti-SLLP1 antibody responses at least 
once throughout the course of their disease.
For some seropositive patients we were even able to 
define immunodominant linear epitopes within the 
SLLP1 protein. In the case of myeloma patient UKE-164, 
for example, we found the SLLP1-specific IgG antibod-
ies to be restricted to a single peptide in the amino acid 
region 161–180 of the whole protein (Figure  3b). How-
ever, antibody responses detected in the blood and in the 
BM of our myeloma patients were mostly quite weak and 
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Figure 1 SLLP1 is specifically expressed by myeloma cells. a RNA expression of SLLP1 was analyzed by RT-PCR in 11 different myeloma cell lines 
(upper row) and bone marrow samples from 11 healthy donors (lower row). Human testis was used as a positive control and housekeeping gene 
GAPDH served as an internal loading control. b Expression of SLLP1 in 5 myeloma cell lines, chronic myeloid leukemia cell line K562, 293 cells, 293 
cells transfected with an SLLP1 expression plasmid and human testis lysate was confirmed by western blot analysis. Beta actin (ACTB) was used as 
an internal control. c Myeloma cell lines (n = 6) were analyzed for SLLP1 expression on a single-cell level applying cytoplasmic staining followed by 
flow cytometry. Grey areas indicate staining intensity with an irrelevant isotype control, black areas show staining with anti-SLLP1 antibody.
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sometimes barely exceeded the threshold defined by our 
analysis of sera from 112 healthy blood donors.
SLLP1 is a potential immunogenic target for T cells
Since humoral and cellular immune responses against 
CTA often occur simultaneously [19], we selected 
10 seropositive patients based on our ELISA results 
to analyze their peripheral blood for the presence of 
SLLP1-specific T cells. However, after one round of 
antigen-specific presensitization none of the investi-
gated patients showed detectable levels of SLLP1-specific 
memory T cell responses (data not shown). Therefore, we 
decided to use a DC-based approach to investigate the 
capability of SLLP1 to induce de novo T cell responses. 
Table 1 Patient characteristics and association with SLLP1 
expression
A total of 177 patients with MM were classified according to the clinical features 
of their disease. Information on cytogenetics (N = 136) was available for fewer 
patients. A patient was considered SLLP1-positive if at least one of all samples 
collected per patient evidenced SLLP1 RNA expression. Importantly, median 
follow-up time was not significantly different between SLLP1-postive and -nega-
tive patients (data not shown). P values as calculated by Chi-square test are indi-
cated in the column on the far right.
Characteristics SLLP1‑positive SLLP1‑negative Sig.
Total (N = 177) 72 (40.7) 105 (59.3)
Age (years)
 ≤60 45 (36.6) 78 (63.4) 0.094
 >60 27 (50.0) 27 (50.0)
Sex
 Male 46 (41.1) 66 (58.9) 0.889
 Female 26 (40.0) 39 (60.0)
Initial stage
 I 10 (38.5) 16 (61.5) 0.928
 II 10 (38.5) 16 (61.5)
 III 52 (41.6) 73 (58.4)
Heavy chain isotype
 IgG 41 (40.2) 61 (59.8) 0.246
 IgA 22 (47.8) 24 (52.2)
 IgM 1 (100.0) 0 (0.0)
 Light chain 8 (28.6) 20 (71.4)
Light chain isotype
 Kappa 43 (37.7) 71 (62.3) 0.281
 Lambda 29 (46.0) 34 (54.0)
Cytogenetics
 Normal karyotype 25 (43.1) 33 (56.9) 0.345
 Del13q14 31 (58.5) 22 (41.5) 0.069
 Del17p13 9 (64.3) 5 (35.7) 0.192
 t(4;14) 9 (81.8) 2 (18.2) 0.018
 Other 13 (38.2) 2 (61.8) 0.198
Table 2 Sample characteristics and association with SLLP1 
expression
A total of 394 samples from 177 patients with MM were classified according to 
clinical features at the time the given sample was collected. Information on per-
centage of BM-infiltrating plasma cells (N = 333), serum paraprotein (N = 275), 
albumin (N  =  352), β2-microglobulin (N  =  169), LDH (N  =  362), hemoglobin 
(N = 306), calcium (N = 365), and creatinine (N = 365) were available for fewer 
samples. Free light chains are only given for the 50 samples from patients with 
light chain myeloma. P values as calculated by Chi-square test are indicated in 
the column on the right.
BM bone marrow, LDH lactate dehydrogenase.
Characteristics SLLP1‑positive SLLP1‑negative Sig.
Total (N = 394) 99 (25.1) 296 (74.9)
Age at time of sample collection (years)
 ≤60 64 (21.1) 240 (78.9) 0.001
 >60 35 (38.9) 55 (61.1)
BM-infiltrating plasma cells (%)
 <10 24 (11.6) 183 (88.4) 0.000
 10–30 19 (33.3) 38 (66.7)
 ≥30 37 (53.6) 32 (46.4)
Serum paraprotein (g/dL)
 <5 (IgG), <3 (IgA) 8 (14.3) 48 (85.7) 0.061
 5–7 (IgG), 3–5 (IgA) 7 (24.1) 22 (75.9)
 >7 (IgG), >5 (IgA) 57 (30.0) 133 (70.0)
Involved serum free light chains (mg/L)
 ≤100 6 (30.0) 14 (70.0) 0.129
 >100 3 (10.0) 27 (90.0)
Serum albumin (g/dL)
 ≥3.5 67 (21.8) 241 (78.2) 0.006
 <3.5 19 (43.2) 25 (56.8)
β2-microglobulin (mg/L)
 <3.5 22 (18.6) 96 (81.4) 0.019
 ≥3.5 18 (35.3) 33 (64.7)
Serum LDH (U/L)
 ≤300 75 (23.0) 251 (77.0) 0.082
 >300 13 (35.1) 23 (63.9)
Hemoglobin (g/dL)
 >10.0 6 (27.3) 16 (72.7) 0.043
 9.9–8.5 16 (41.0) 23 (59.0)
 <8.5 55 (22.4) 190 (77.6)
Serum calcium (mmol/L)
 ≤2.6 79 (22.8) 267 (77.2) 0.015
 >2.6 9 (47.4) 10 (52.6)
Serum creatinine (mg/dL)
 ≤2.0 78 (22.5) 269 (77.5) 0.008
 >2.0 9 (50.0) 9 (50.0)
Treatment status
 Untreated 25 (44.6) 31 (55.4) 0.003
 Chemotherapy 8 (22.2) 28 (77.8)
 AutoSCT 19 (29.2) 46 (70.8)
 AlloSCT 47 (19.9) 189 (80.1)
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To this end, T cells from 3 healthy donors were repeat-
edly stimulated with autologous monocyte-derived DCs 
loaded with peptide pools containing 10 and 11 over-
lapping SLLP1 20-mer peptides, respectively. After 
6–8 weeks of culture and repeated rounds of restimula-
tion T cell lines were tested for the presence of SLLP1 
reactivity. We detected anti-SLLP1 T cell responses 
among lines of all three donors tested (Figure  4a–c). 
These responses were directed against a variety of differ-
ent SLLP1 epitopes with epitope SLLP1101–120 eliciting 
specific T cells in all donors tested (Figure 4a–c). When 
we analyzed the SLLP1-specific T cell lines generated by 
flow cytometry we were able to confirm that they spe-
cifically produced IFN-γ upon exposure to their cognate 
antigen (Figure 5a).
In a final step, we isolated a total of five different T cell 
clones (TCC) from the SLLP1-specific T cell lines gen-
erated. Clonality was confirmed by T cell receptor beta 
chain variable usage in all the TCC (Figure 5b). When we 
analyzed the phenotype of the TCC we found that all the 
clones were CD4+ (Figure 5c). Importantly, we were able 
to sequence the T cell receptors of all the 5 SLLP-specific 
TCC (Table 3) facilitating their use in future approaches 
targeting SLLP1 in myeloma, for example by the adop-
tive transfer of TCR-transduced T cells. Based on limited 
patient material we were not able to test tumor recogni-
tion by our SLLP1-specific T cell clones. However, stud-
ies evaluating safety and efficacy of the adoptive transfer 
of SLLP1 TCR-transduced T cells are currently ongoing 
in our lab.
Discussion
We have here analyzed the value of a potential new tar-
get structure, cancer-testis antigen SLLP1, for the treat-
ment of MM. One major criterion for the applicability 
of a given tumor antigen for cancer immunotherapy is 
that it shows a tumor-restricted expression and is absent 
from the essential types of healthy tissues. Condomines 
and coworkers previously observed RNA expression of 
SLLP1 in a proportion of normal peripheral blood B cells 
and in polyclonal plasmablasts generated in vitro from 
normal B cells but not in BM plasma cells from healthy 
donors [20]. In contrast, Wang et  al. did not detect any 
SLLP1 expression in peripheral blood and BM samples 
from healthy donors [11]. We were able to confirm our 
previous finding that SLLP1 is absent from whole BM 
cells from healthy donors [21] in our current investi-
gation. All available evidence, therefore, supports the 
idea that SLLP1 is not present in normal hematopoietic 
cells and in that sense shows a tumor-restricted expres-
sion. In addition, publicly available databases indicate an 
absence of SLLP1 from most normal epithelial tissues 
[22]. However, there is one notable exception with sig-
nificant RNA-level expression in the pancreas. While this 
does not necessarily translate to protein-level expression, 
future studies should perform a careful assessment of 
SLLP1 expression in such normal tissues before consider-
ing SLLP1 as a therapeutic target in MM.
Another important point is that the tumor antigen 
in question should show a sufficiently frequent tumor-
related expression to enable its use in a substantial 
Figure 2 Expression of SLLP1 correlates with a worse prognosis in 
patients treated with alloSCT. A total of 84 patients who had received 
alloSCT were divided into to two groups according to the SLLP1 
expression status in their bone marrow as determined by RT-PCR. 
Curves represent Kaplan–Meier estimates of progression-free survival 
(a) and overall survival (b) from application of alloSCT until end of 
observation.
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proportion of patients with a given malignancy. We 
observed that the vast majority of myeloma cell lines 
expressed SLLP1 on the RNA and protein levels. In addi-
tion, we detected SLLP1 expression in the PC-contain-
ing BM of 44% of patients with newly diagnosed MM. 
These findings are in accordance with previous results 
on SLLP1 expression in myeloma. SLLP1 has been found 
to be expressed in hematologic malignancies [11, 21, 
23] including MM [11, 20]. In an initial study, 6 out of 
17 myeloma patients analyzed were found to evidence 
SLLP1 RNA expression [11]. Another study observed an 
expression of SLLP1 in 33% of samples from 64 myeloma 
patients using microarray technology [20]. Overall, the 
combined data suggest that SLLP1 is among the CTA 
most frequently expressed in MM.
A given tumor antigen is probably better suited as a 
therapeutic target if it has a central function in the biol-
ogy the respective cancer type because this would keep 
the malignancy from downregulating its expression 
under the selective pressure of an immunotherapeutic 
approach. The biological function of SLLP1 in human 
cancers has never been investigated but our current 
results indicate that this CTA might very well play a role 
in the development and/or progression of MM as we and 
others have demonstrated for other CTAs frequently 
expressed in MM [24, 25]. We found, for example, SLLP1 
expression in all our patient-derived whole BM samples 
to correlate with a number of negative prognostic fac-
tors including the patient’s age, the number of BM-infil-
trating plasma cells, as well as serum levels of albumin, 
Figure 3 Myeloma patients occasionally develop spontaneous IgG antibody responses against SLLP1. Based on the unavailability of recombinant 
full-length SLLP1 protein with a sufficient quality, we decided to use SLLP1 20-mer peptides overlapping by 10 amino acids for the detection of 
spontaneous anti-SLLP1 IgG antibody responses. a For the ELISA assays, plates were coated with two pools of peptides containing SLLP1 peptides 
1–10 (pool SLLP1-1; left) and 11–21 (pool SLLP1-2; right), respectively, Dots indicate intensity of the signal as measured by an absorbance reader.  
b Target epitopes of the SLLP1-specific antibody response of MM patient UKE-164 were identified using single overlapping 20-mer peptides span-
ning the complete sequence of SLLP1 in an ELISA assay. Recombinant influenza nucleoprotein (NP) and tetanus toxoid (TT) were used as positive 
controls, recombinant SSX-2 protein served as an irrelevant control protein. Bars indicate intensity (mean + SEM) of the signal against the given 
epitope. All results were validated by three independent experiments.
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β2-microglobulin, hemoglobin, and creatinine. In addi-
tion, we observed an extraordinarily frequent expression 
of SLLP1 in patients with adverse cytogenetics, in par-
ticular patients who evidenced a t(4;14). One finding that 
also pointed to a role of SLLP1 in the pathophysiology of 
MM is our observation that SLLP1 expression was to a 
certain degree associated with an adverse prognosis in 
patients treated with alloSCT who had evidenced SLLP1 
expression in their BM at least at one time point after 
transplant. It is not entirely clear why this association was 
only present in the group of patients who had received 
alloSCT as part of their overall therapeutic concept, 
however, it could simply be related to the fact that these 
patients represented the largest group included in our 
study. On the other hand, SLLP1 could potentially rep-
resent a target for an immunologic graft-versus-myeloma 
Figure 4 Induction of T cell specificity against multiple SLLP1 peptide epitopes. SLLP1-reactive T cell cultures were generated from PBMC from 
three healthy donors: a UKE-1, b UKE-2, and c UKE-3. Each plot represents an SLLP1-specific T cell line (TCL). IFN-γ secretion was measured in ELIS-
POT assay after restimulation with T-APC loaded with single peptides. T cells stimulated with unloaded T-APC were used as background controls (no 
peptide). Bars indicate the number of IFN-γ spots per 25,000 T cells (mean + SEM). Black bars indicate significant reactivity above the background 
value + 3STD.
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effect [26–28] and we cannot exclude the possibility that 
our observation of a significantly lower expression of 
SLLP1 after alloSCT is based on a transplant-induced 
eradication of SLLP1-expressing tumor cells from the 
patients’ BM.
It might be of benefit for the therapeutic value of a 
certain antigen if it is capable of spontaneously induc-
ing immune responses because immunotherapeutic 
interventions could potentially build on such a preex-
isting immunity. Our previous investigations suggested 
that antibody responses are commonly associated with 
T cell responses against the same antigen [19, 29, 30]. 
Therefore, we decided to first screen our large collection 
of patient samples for humoral responses against SLLP1 
and then focus on the SLLP1-antibody-positive patients 
and analyze them for the presence SLLP1-specific T 
cells. We found that about 9.5% of our patients evidenced 
antibody responses against SLLP1. The prevalence of 
humoral responses against SLLP1 would, therefore, 
be significantly higher than the frequency of antibody 
responses against two other CTA, namely NY-ESO-1 and 
SSX-2, we had observed in one of our very recent stud-
ies [30]. However, in contrast to the latter two CTA, anti-
body responses against SLLP1 were mostly low-titered. 
Consequently, a comparably diminished uptake of SLLP1 
immune complexes by professional APC and the result-
ing compromised presentation of tumor antigen to T 






















Figure 5 Phenotype of SLLP1-specific T cells. a T cell lines were restimulated with their cognate SLLP131–50 peptide or irrelevant control peptide 
and secretion of IFN-γ was measured on the cell surface by flow cytometry. b T cell clone number 1 (TCC1) was stained with an antibody cocktail 
containing three different TRBV antibodies (PE, FITC, PE/FITC). The gray dot plot represents the isotype control. c SLLP-1-specific T cell clones ana-
lyzed phenotypically using staining with anti-CD4 and anti-CD8 antibodies followed by flow cytometry.
Table 3 Sequencing of SLLP1-specific T cell receptors
Naming of TCR chains according to IMGT nomenclature. SLLP1 peptide and CDR3 sequence are displayed using amino acid single letter code. T cell clone purity was 
determined by flow cytometry.
TRBV/TRAV T cell receptor variable beta/alpha chain, CDR3 complementarity determining region 3.
Peptide Sequence Purity (%) TRBV CDR3 Beta TRAV CDR3 Alpha
TCC 1 31–50 SCLSSQSSALSQSGGGSTSA 100 11-2 CASSLGAGGYTEAFF 8-3*01 CAVGGAGNMLTF
TCC 2 51–70 AGIEARSRALRRRWCPAGIM 98 10-3 CAISDGISGNTIYF 14 CAMRVGSDGQKLLF
TCC 3 1–20 MVSALRGAPLIRVHSSPVSS – – – – –
TCC 4 111–130 SLADWVCLAYFTSGFNAAAL 99 12 CASSLTENIQYF 13-1 CAASSGGSNYKLTF
TCC 5 51–70 AGIEARSRALRRRWCPAGIM – 12-4 CASSFGQPNLNYGYTF 19 CALSEAGFQKLVF
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finding that none of the seropositive patients evidenced 
spontaneous T cell responses against SLLP1 [31–33].
We did not detect any surface expression of SLLP1 on 
myeloma cells by flow cytometry and CTA are generally 
known for their intracellular protein expression [34]. As a 
consequence, these tumor antigens cannot be targeted by 
therapeutic monoclonal antibodies or chimeric antigen 
receptor (CAR)-transduced cells. Classical T cell-based 
approaches such as tumor vaccination seem more appro-
priate, however, two large phase III vaccination studies 
using recombinant proteins of CTA MAGE-A3 for lung 
cancer and melanoma, the MAGRIT and DERMA trials, 
have recently failed. We, therefore, believe that alterna-
tive modes of treatment, such as the adoptive transfer of 
T cell receptor (TCR)-transduced T cells are probably 
more likely to show clinical efficacy in the immunother-
apy of cancer using CTA as targets. Accordingly, clinical 
studies using CTA NY-ESO-1-specific TCR-transduced 
T cells for the treatment of patients with melanoma and 
synovial cell sarcoma have shown remarkable response 
rates [35, 36]. On the other hand, one study applying T 
cells transduced with a TCR specific for CTA MAGE-
A3 was associated with severe toxicity based on the fact 
that a homologue to MAGE-A3, namely MAGE-A12, 
was expressed in the patients’ brain tissue [37]. It might, 
therefore, be of advantage that SLLP1 does not show any 
homology to such antigens known for their unspecific 
expression in healthy tissues.
In conclusion, we have demonstrated here that can-
cer-testis antigen SLLP1 shows a tumor-restricted 
expression pattern and is present in the tumor cells of a 
substantial proportion of patients with MM. The expres-
sion of SLLP1 is associated with a number of adverse 
clinicopathological parameters and a worse outcome of 
myeloma patients. Spontaneous anti-SLLP1 humoral 
immunity occurs comparably frequently in MM but anti-
body responses are mostly low-titered and spontane-
ous T cell responses were absent. However, de novo T 
cell responses against SLLP1, which can be exploited for 
adoptive cell transfer approaches, can easily be induced. 
Thus, SLLP1 represents a promising target for the immu-
notherapy of MM and, hopefully, our combined findings 
will lead to the development of effective immunothera-
peutic approaches for patients with this fatal hematologic 
malignancy.
Conclusions
Most patients with MM will relapse after an initially 
successful therapy and eventually succumb to their dis-
ease. Immunotherapeutic approaches could contribute 
to eradicating chemotherapy-resistant tumor cells from 
the patients’ BM and facilitate prolonged remissions or 
even cures. Evaluating cancer-testis antigen SLLP1 as a 
potential immunotherapeutic target for MM we found 
myeloma-specific expression of the target antigen in the 
BM of a substantial proportion of myeloma patients. 
Expression of SLLP1 was associated with adverse cytoge-
netics and with a number of other negative prognostic 
factors. Among patients treated with allogeneic stem cell 
transplantation those with SLLP1 expression showed a 
reduced overall survival. Finally, we detected spontane-
ous anti-SLLP humoral immunity in myeloma patients 
and SLLP1-specific T cells could readily be induced in 
vitro after stimulation with SLLP1. Our combined obser-
vations suggest that cancer-testis antigen SLLP1 repre-
sents a promising target for the immunotherapy of MM, 
in particular for the adoptive transfer of T cell receptor-
transduced T cells.
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